Please assess the completion status of the following clinical trial:

Trial Title: Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients may be enrolled in the trial if all of the following criteria have been met:~* Symptomatic SVD defined as~  * History of clinical lacunar stroke in the last 5 years with a corresponding small subcortical infarct visible on MRI scan or CT scan\* compatible with the clinical syndrome.~    \*On MRI, recent infarct is defined as a diffusion-weighted imaging (DWI) lesion on the acute MRI scan. On CT, recent infarct is defined as a novel infarct on CT within 3 weeks after the event that was not visible on the admission CT. Patients admitted to the hospital with an obvious lacunar syndrome and an admission CT/CT perfusion compatible with a lacunar infarct but without an MRI in the (sub)acute stage and no repeat CT performed in the context of clinical care can be recruited for TREAT-SVDs. After providing informed consent they will be invited for the screening visit including a 3T MRI. The 3T MRI will be used to verify the presence of a new lesion, relative to the admission CT, compatible with a lacunar infarct and compatible with the lacunar syndrome. If such a lesion is present the patient will undergo the further TREAT-SVDs workup. If no such lesion is observed the patient will be excluded from the study and considered as a screening failure.~ * or cognitive impairment defined as visiting a memory clinic with cognitive complaints, objective cognitive impairment\*, and capacity to consent, and with confluent deep white matter hyperintensities (WMH) on MRI (defined on the Fazekas scale as deep WMH score ≥ 2)~    \*concluded by the treating physician based on a validated cognitive measurement tool (for example but not limited to MoCA or CAMCOG)~ * or a diagnosis of CADASIL established by molecular genetic testing of the NOTCH3 gene (presence of an archetypical, cysteine-affecting mutation) or the presence of granular osmiophilic material in ultrastructural, electron microscopy analysis of skin biopsy~* Indication for antihypertensive treatment (as defined by meeting one of the following):~  * Hypertension defined as SBP ≥ 140 mmHg or diastolic BP (DBP) ≥ 90 mmHg without antihypertensive treatment or use of an antihypertensive drug for previously diagnosed hypertension~ * Prior history of stroke or transient ischaemic attack (TIA)~* Age 18 years or older~* Written informed consent~Exclusion Criteria:~Patients will be excluded from the trial for any of the following reasons:~* Inclusion criteria are not met~* Unwillingness or inability to give written consent~* Pregnant or breastfeeding women, women of childbearing age not taking contraception.~Acceptable contraception in women of childbearing age is a highly effective contraceptive measure as defined by the Clinical Trials Facilitation Group and includes combined (oestrogen and progesterone containing) or progesterone-only contraception associated with inhibition of ovulation, or intrauterine device, or bilateral tubal occlusion.~* Contraindications to MRI (pacemaker, aneurysm clip, cochlear implant etc.)~* Other major neurological or psychiatric conditions affecting the brain and interfering with the trial design (e.g. multiple sclerosis)~* In case of clinical lacunar stroke syndrome other causes of stroke such as~  * ≥ 50% luminal stenosis (NASCET) in large arteries supplying the area of ischaemia~ * major-risk cardioembolic source of embolism (permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumours, mitral stenosis, recent (\< 4 weeks) myocardial infarction, left ventricular ejection fraction less than 30%, valvular vegetations, or infective endocarditis)~ * other specific causes of stroke identified (e.g. arteritis, dissection, migraine/vasospasm, drug misuse)~* Other stroke risk factor requiring immediate intervention that would preclude involvement in the trial~* Renal impairment (eGFR \< 35ml/min)~* Life expectancy \< 2 years~* Use of \> 2 antihypertensive drugs at maximum dose or equivalent (one drug at the maximum dose and two drugs at half of the maximum dose) for an appropriate BP control~* Contraindications to the applied antihypertensive drugs as known~  * Severe aortic stenosis~ * Bilateral renal artery stenosis~ * Severe arterial circulatory disorders~ * Atrioventricular block II° or III° or sick sinus syndrome~ * Heart failure (NYHA III or IV)~ * Bradycardia, resting heart rate \< 50/min~ * Bronchospastic diseases such as severe bronchial asthma~ * Severe hepatic dysfunction such as liver cirrhosis~ * Use of monoamine oxidase (MAO)-A-blockers~ * Use of simvastatin \> 20mg/d~ * Metabolic acidosis~ * Disturbed electrolyte homeostasis such as hypercalcaemia, hypokalaemia, and hyponatraemia~ * Symptomatic hyperuricaemia (gout)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
- Arm B (Type: ACTIVE_COMPARATOR): Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
- Arm C (Type: ACTIVE_COMPARATOR): Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).